ClinicalTrials.gg
Sign In

Macular Degeneration clinical trials

The registry lists 1,459 studies for Macular Degeneration across more than 10 countries. 238 are recruiting or about to start. 1,131 of them are mainly about Macular Degeneration (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 4 narrower conditions too, such as Macular Edema: 2,306 studies, 337 open.

ClinicalTrials.gov finds 2,174 studies for Macular Degeneration. How that becomes 1,458 here

This page counts the studies the registry files under Macular Degeneration, and those it files under no condition that list Macular Degenerationthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 2,174Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −524Filed under a narrower condition, counted on its own pageMacular Edema 376 · Geographic Atrophy 62 · Stargardt Disease 47 · Wet Macular Degeneration 37
  3. −81List Macular Degeneration as a condition, but the registry did not file them under itMost often written as “Neovascular Age-related Macular Degeneration” (15), “Diabetic Maculopathy” (9), and “Neovascular Age-related Macular Degeneration (nAMD)” (6). The registry filed 10 of them under no condition at all, and the others under other conditions only, most often Retinal Vein Occlusion (15) and Choroidal Neovascularization (8).
  4. −111Match it another way59 name it in the title, 8 in a keyword, and 44 by a synonym or other text the search reads.
  5. 1,458The count on this page285 of them list Macular Degeneration in their own words; the registry filed them under no condition.

Get an email when these change. Save the Macular Degeneration studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
822
Recruiting
166
Status unknown
161
Terminated
123
Active, not recruiting
67
Not yet recruiting
62

Phase

Phase 2
348
Phase 1
243
Phase 3
209
Phase 4
104
Early Phase 1
14

Where

United States
645
France
120
Germany
110
United Kingdom
108
China
106
Italy
97

Who runs them

Novartis Pharmaceuticals (63) · National Eye Institute (NEI) (55) · Bayer (30) · Notal Vision Ltd. (21) · Medical University of Vienna (19) · Alcon Research (18) · Regeneron Pharmaceuticals (17) · Pfizer (17)

What is being tested here

Drugs under test in Macular Degeneration studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Faricimab6210
OLN324223
EYE201222
Ranibizumab128101
Pegcetacoplan113
Cp-547632103
Chloroprocaine102
Onzemipgene parvec112
Disulfiram102
Apraclonidine101

Drug classes tested here Angiogenesis inhibitors 7 open · Tyrosine kinase inhibitors (TKIs) 1 open · Local anesthetics 1 open · Corticosteroids 24 · mTOR inhibitors 7

Coming up

45phase 3 studies under way
84studies finish main data collection within a year13 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger. 19 (11%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 35 (21%) take healthy volunteers.

Recruiting studies that take each age, of 166
AgeWomenMen
1015 (9%)15 (9%)
1852 (31%)52 (31%)
3056 (34%)56 (34%)
4058 (35%)58 (35%)
50131 (79%)131 (79%)
65163 (98%)163 (98%)
75162 (98%)162 (98%)
85153 (92%)153 (92%)

Across all 1,459 studies, recruiting or not: 3% stop at 75 or younger and 2% at 65; 8% take children; <1% are for women only and <1% for men only; 17% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Macular Degeneration studies take

Of 83 phase 2 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 118 mo10–30 · 75 studies15 mo9–27 · 60 studies—
Phase 1/232 mo18–65 · 52 studies——
Phase 224 mo16–35 · 83 studies22 mo15–30 · 66 studies—
Phase 324 mo20–35 · 83 studies24 mo20–33 · 77 studies—
Phase 426 mo14–39 · 45 studies27 mo19–36 · 24 studies—
Interventional, no phase37 mo17–60 · 132 studies—41 mo17–56 · 104 studies
Observational45 mo16–77 · 161 studies42 mo14–69 · 56 studies48 mo20–98 · 105 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Started recruiting3

Newly registered6

Show 1 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,459. Browse all 1,459 → or search them.